Concepedia

Reshma Rangwala

RR

Statistics

Publications

29

Citations

19.6K

H-Index

21

Active since

2002

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Sydney

Westmead Hospital

Meir Medical Center

Royal Marsden Hospital

Reshma Rangwala is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

2002–2022

29

Publications

29

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 9.8K citations · Full text

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.1K citations · Full text

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology · 2017 · 522 citations

Combined MTOR and autophagy inhibition

Reshma Rangwala, Yunyoung C Chang, Janice Hu et al. · Autophagy · 2014 · 411 citations · Full text

, , +18

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 367 citations

, , +8

1–5 of 29